---
document_datetime: 2025-12-02 06:00:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/resolor.html
document_name: resolor.html
version: success
processing_time: 0.1140955
conversion_datetime: 2025-12-29 19:30:39.725485
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Resolor

[RSS](/en/individual-human-medicine.xml/66618)

##### Authorised

This medicine is authorised for use in the European Union

prucalopride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Resolor](#news-on)
- [More information on Resolor](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Resolor. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Resolor.

Expand section

Collapse section

## What is Resolor?

Resolor is a medicine that contains the active substance prucalopride. It is available as tablets (1 and 2 mg).

## What is Resolor used for?

Resolor is used to treat symptoms of chronic (long-term) constipation in adults for whom laxatives (medicines that trigger bowel movements) do not work well enough.

The medicine can only be obtained with a prescription.

## How is Resolor used?

The recommended dose of Resolor is 2 mg taken once a day. Patients aged over 65 years should start with a 1 mg dose once a day, and this can be increased to 2 mg once a day if needed.

## How does Resolor work?

The active substance in Resolor, prucalopride, is a '5-HT 4 receptor agonist'. This means that it works like a substance in the body called 5-hydroxytryptamine (5-HT, also known as serotonin) and attaches to receptors for 5-HT in the gut called '5-HT 4 receptors'.

When 5-HT binds to these receptors, it normally stimulates movement in the gut. In the same way, when prucalopride attaches to and stimulates these receptors, it increases this movement and allows the bowels to empty faster.

## How has Resolor been studied?

Resolor (2 or 4 mg once a day) was compared with placebo (a dummy treatment) in three main studies involving 1,999 patients with chronic constipation, 88% of whom were women. The patients had not responded well enough to previous treatment with laxatives.

Resolor 2 mg once a day was also compared with placebo in another main study involving 374 men with chronic constipation.

The main measure of effectiveness in the studies was the number of patients who completely emptied their bowels at least three times a week over a 12 week period without the help of laxatives.

## What benefit has Resolor shown during the studies?

Resolor was more effective than placebo at treating chronic constipation. Over the 12-week period, 24% (151 out of 640) of patients who received Resolor 2 mg completely emptied their bowels at least three times a week, compared with 11% (73 out of 645) of patients who received placebo. The result from patients who received Resolor at the higher dose of 4 mg was similar to those who took the 2 mg dose.

In the study of men with chronic constipation, 38% of patients treated with Resolor 2 mg (67 out of 177) completely emptied their bowels at least three times a week, compared with 18% of those given placebo (32 out of 181).

## What is the risk associated with Resolor?

The most common side effects with Resolor (seen in more than 1 patient in 10) are headache, nausea (feeling sick), diarrhoea and abdominal (tummy) pain. For the full list of all side effects reported with Resolor, see the package leaflet.

Resolor must not be used in patients with kidney problems requiring dialysis (a blood clearance technique). It must also not be used in patients with intestinal perforation or obstruction, severe inflammatory conditions of the intestines such as Crohn's disease, ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) and toxic megacolon and megarectum (very serious complications of colitis). For the full list of restrictions, see the package leaflet.

## Why has Resolor been approved?

The CHMP decided that Resolor's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Resolor?

A risk-management plan has been developed to ensure that Resolor is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Resolor, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Resolor

The European Commission granted a marketing authorisation valid throughout the European Union for Resolor on 15 October 2009.

For more information about treatment with Resolor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Resolor : EPAR - Summary for the public

English (EN) (74.45 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 20/08/2015

[View](/en/documents/overview/resolor-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-223)

български (BG) (103.23 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/bg/documents/overview/resolor-epar-summary-public_bg.pdf)

español (ES) (79.72 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/es/documents/overview/resolor-epar-summary-public_es.pdf)

čeština (CS) (99.92 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/cs/documents/overview/resolor-epar-summary-public_cs.pdf)

dansk (DA) (79.49 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/da/documents/overview/resolor-epar-summary-public_da.pdf)

Deutsch (DE) (80.83 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/de/documents/overview/resolor-epar-summary-public_de.pdf)

eesti keel (ET) (79.04 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/et/documents/overview/resolor-epar-summary-public_et.pdf)

ελληνικά (EL) (104.51 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/el/documents/overview/resolor-epar-summary-public_el.pdf)

français (FR) (80.82 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/fr/documents/overview/resolor-epar-summary-public_fr.pdf)

hrvatski (HR) (96.4 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/hr/documents/overview/resolor-epar-summary-public_hr.pdf)

italiano (IT) (79.88 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/it/documents/overview/resolor-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.87 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/lv/documents/overview/resolor-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.11 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/lt/documents/overview/resolor-epar-summary-public_lt.pdf)

magyar (HU) (95.49 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/hu/documents/overview/resolor-epar-summary-public_hu.pdf)

Malti (MT) (100.38 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/mt/documents/overview/resolor-epar-summary-public_mt.pdf)

Nederlands (NL) (79.67 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/nl/documents/overview/resolor-epar-summary-public_nl.pdf)

polski (PL) (100.26 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/pl/documents/overview/resolor-epar-summary-public_pl.pdf)

português (PT) (80.19 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/pt/documents/overview/resolor-epar-summary-public_pt.pdf)

română (RO) (96.63 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/ro/documents/overview/resolor-epar-summary-public_ro.pdf)

slovenčina (SK) (99.88 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/sk/documents/overview/resolor-epar-summary-public_sk.pdf)

slovenščina (SL) (94.9 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/sl/documents/overview/resolor-epar-summary-public_sl.pdf)

Suomi (FI) (78.92 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/fi/documents/overview/resolor-epar-summary-public_fi.pdf)

svenska (SV) (79.68 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

20/08/2015

[View](/sv/documents/overview/resolor-epar-summary-public_sv.pdf)

## Product information

Resolor : EPAR - Product Information

English (EN) (224.58 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 15/12/2022

[View](/en/documents/product-information/resolor-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-338)

български (BG) (259.42 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/bg/documents/product-information/resolor-epar-product-information_bg.pdf)

español (ES) (233.04 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/es/documents/product-information/resolor-epar-product-information_es.pdf)

čeština (CS) (241.66 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/cs/documents/product-information/resolor-epar-product-information_cs.pdf)

dansk (DA) (241.96 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/da/documents/product-information/resolor-epar-product-information_da.pdf)

Deutsch (DE) (247.56 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/de/documents/product-information/resolor-epar-product-information_de.pdf)

eesti keel (ET) (232.99 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/et/documents/product-information/resolor-epar-product-information_et.pdf)

ελληνικά (EL) (276.65 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/el/documents/product-information/resolor-epar-product-information_el.pdf)

français (FR) (240.85 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/fr/documents/product-information/resolor-epar-product-information_fr.pdf)

hrvatski (HR) (233.28 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/hr/documents/product-information/resolor-epar-product-information_hr.pdf)

íslenska (IS) (240.04 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/is/documents/product-information/resolor-epar-product-information_is.pdf)

italiano (IT) (233.9 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/it/documents/product-information/resolor-epar-product-information_it.pdf)

latviešu valoda (LV) (256.91 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/lv/documents/product-information/resolor-epar-product-information_lv.pdf)

lietuvių kalba (LT) (248.24 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/lt/documents/product-information/resolor-epar-product-information_lt.pdf)

magyar (HU) (249.56 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/hu/documents/product-information/resolor-epar-product-information_hu.pdf)

Malti (MT) (290.74 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/mt/documents/product-information/resolor-epar-product-information_mt.pdf)

Nederlands (NL) (231.11 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/nl/documents/product-information/resolor-epar-product-information_nl.pdf)

norsk (NO) (229.34 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/no/documents/product-information/resolor-epar-product-information_no.pdf)

polski (PL) (263.57 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/pl/documents/product-information/resolor-epar-product-information_pl.pdf)

português (PT) (238.01 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/pt/documents/product-information/resolor-epar-product-information_pt.pdf)

română (RO) (248.4 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/ro/documents/product-information/resolor-epar-product-information_ro.pdf)

slovenčina (SK) (247.07 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/sk/documents/product-information/resolor-epar-product-information_sk.pdf)

slovenščina (SL) (235.43 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/sl/documents/product-information/resolor-epar-product-information_sl.pdf)

Suomi (FI) (229.07 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/fi/documents/product-information/resolor-epar-product-information_fi.pdf)

svenska (SV) (243.25 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

15/12/2022

[View](/sv/documents/product-information/resolor-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0057 14/12/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Resolor : EPAR - All Authorised presentations

English (EN) (24.36 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 02/03/2018

[View](/en/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-605)

български (BG) (120.34 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/bg/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.7 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/es/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_es.pdf)

čeština (CS) (75.85 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/cs/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.05 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/da/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.4 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/de/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.68 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/et/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (119.25 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/el/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_el.pdf)

français (FR) (43.39 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/fr/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (102.75 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/hr/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.79 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/is/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_is.pdf)

italiano (IT) (43.39 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/it/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (120.2 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/lv/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (119.29 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/lt/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.33 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/hu/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (122.69 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/mt/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.41 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/nl/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/no/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_no.pdf)

polski (PL) (79.57 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/pl/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.53 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/pt/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_pt.pdf)

română (RO) (117.08 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/ro/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (78.8 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/sk/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.45 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/sl/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.44 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/fi/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.16 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

02/03/2018

[View](/sv/documents/all-authorised-presentations/resolor-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Resolor Active substance prucalopride succinate International non-proprietary name (INN) or common name prucalopride Therapeutic area (MeSH) Constipation Anatomical therapeutic chemical (ATC) code A06AX05

### Pharmacotherapeutic group

Other drugs for constipation

### Therapeutic indication

Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

## Authorisation details

EMA product number EMEA/H/C/001012 Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland

Block 2 Miesian Plaza

Marketing authorisation issued 14/10/2009 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Resolor : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (236.27 KB - PDF)

**First published:** 10/08/2010

**Last updated:** 12/09/2024

[View](/en/documents/procedural-steps-after/resolor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Resolor-H-C-001012-P46-023 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/322882/2024

English (EN) (480.48 KB - PDF)

**First published:** 12/09/2024

[View](/en/documents/variation-report/resolor-h-c-001012-p46-023-epar-assessment-report_en.pdf)

Resolor : EPAR - Paediatric investigation plan compliance statement

Adopted

Reference Number: EMA/661059/2019

English (EN) (119.19 KB - PDF)

**First published:** 05/12/2019

[View](/en/documents/pip-compliance/resolor-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Resolor-H-C-1012-II-0034 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/772340/2014

English (EN) (3.06 MB - PDF)

**First published:** 22/07/2015

**Last updated:** 22/07/2015

[View](/en/documents/variation-report/resolor-h-c-1012-ii-0034-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Resolor

Adopted

Reference Number: EMA/CHMP/234861/2015

English (EN) (66.56 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 24/04/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-resolor_en.pdf)

## Initial marketing authorisation documents

Resolor : EPAR - Public assessment report

English (EN) (848.14 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 17/11/2009

[View](/en/documents/assessment-report/resolor-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Resolor

Reference Number: EMEA/CHMP/449050/2009

English (EN) (32.54 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 23/07/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-resolor_en.pdf)

#### News on Resolor

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

#### More information on Resolor

- [EMEA-000459-PIP01-08-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000459-pip01-08-m02)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/09/2024

## Share this page

[Back to top](#main-content)